JP2020501517A5 - - Google Patents

Download PDF

Info

Publication number
JP2020501517A5
JP2020501517A5 JP2019522657A JP2019522657A JP2020501517A5 JP 2020501517 A5 JP2020501517 A5 JP 2020501517A5 JP 2019522657 A JP2019522657 A JP 2019522657A JP 2019522657 A JP2019522657 A JP 2019522657A JP 2020501517 A5 JP2020501517 A5 JP 2020501517A5
Authority
JP
Japan
Prior art keywords
cancer
cdna
subject
drug
droplets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019522657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020501517A (ja
JP7195252B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/058855 external-priority patent/WO2018081625A2/en
Publication of JP2020501517A publication Critical patent/JP2020501517A/ja
Publication of JP2020501517A5 publication Critical patent/JP2020501517A5/ja
Priority to JP2022142901A priority Critical patent/JP7441907B2/ja
Application granted granted Critical
Publication of JP7195252B2 publication Critical patent/JP7195252B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019522657A 2016-10-27 2017-10-27 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析 Active JP7195252B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022142901A JP7441907B2 (ja) 2016-10-27 2022-09-08 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662413952P 2016-10-27 2016-10-27
US62/413,952 2016-10-27
PCT/US2017/058855 WO2018081625A2 (en) 2016-10-27 2017-10-27 Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022142901A Division JP7441907B2 (ja) 2016-10-27 2022-09-08 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析

Publications (3)

Publication Number Publication Date
JP2020501517A JP2020501517A (ja) 2020-01-23
JP2020501517A5 true JP2020501517A5 (https=) 2020-12-03
JP7195252B2 JP7195252B2 (ja) 2022-12-23

Family

ID=62025512

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019522657A Active JP7195252B2 (ja) 2016-10-27 2017-10-27 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析
JP2022142901A Active JP7441907B2 (ja) 2016-10-27 2022-09-08 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022142901A Active JP7441907B2 (ja) 2016-10-27 2022-09-08 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析

Country Status (5)

Country Link
US (2) US11371101B2 (https=)
EP (2) EP3985127A1 (https=)
JP (2) JP7195252B2 (https=)
CN (1) CN110050075B (https=)
WO (1) WO2018081625A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3274476B1 (en) 2015-03-25 2023-06-07 The General Hospital Corporation Digital analysis of circulating tumor cells in blood samples
EP3985127A1 (en) * 2016-10-27 2022-04-20 The General Hospital Corporation Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers
WO2020006098A2 (en) * 2018-06-26 2020-01-02 Children's National Medical Center Tumor-associated markers for detection of minimal residual disease using digital droplet pcr
EP3880198A4 (en) 2018-11-14 2022-08-10 The Broad Institute, Inc. ARYHYDROCARBON RECEPTOR (AHR) ACTIVATOR COMPOUNDS AS CANCER THERAPEUTICS
TWI790399B (zh) * 2019-08-30 2023-01-21 長庚大學 循環腫瘤細胞資訊評估方法及其分析方法
CN114830258A (zh) * 2019-09-16 2022-07-29 斯坦福大学托管董事会 基于乳腺癌的分子表征的治疗方法
JP7534426B2 (ja) * 2020-09-09 2024-08-14 株式会社日立ハイテク 代謝物パネルによるがん検査法
CN112698033A (zh) * 2020-12-09 2021-04-23 复旦大学附属中山医院 一种血源性外泌体her2的检测方法及其应用
US20240159632A1 (en) * 2021-03-16 2024-05-16 Sony Group Corporation Closed-system automated sample sorting system
CN113292643A (zh) * 2021-05-31 2021-08-24 南京市第二医院 一种肝癌肿瘤标志物及其应用
EP4366873A4 (en) * 2021-07-08 2025-08-06 Ourotech Inc SYSTEMS AND METHODS FOR PREDICTING TREATMENT EFFECTIVENESS
CN114395622A (zh) * 2021-12-13 2022-04-26 深圳先进技术研究院 一种利用数字pcr检测循环肿瘤细胞egfr基因突变的方法及其应用
WO2025259592A1 (en) * 2024-06-10 2025-12-18 Genecentric Therapeutics, Inc. Therapeutic predictive response signatures and uses thereof in cancer patients

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US889A (en) 1838-08-20 Mode of constructing metal bench-vises
US8535A (en) 1851-11-18 Stove-geate
DE29623597U1 (de) 1996-11-08 1999-01-07 Eppendorf - Netheler - Hinz Gmbh, 22339 Hamburg Temperierblock mit Temperiereinrichtungen
US20080050393A1 (en) 1998-12-03 2008-02-28 Tang Y Tom Novel nucleic acids and polypeptides
CA2311201A1 (en) 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
US20030143539A1 (en) 2000-12-08 2003-07-31 Francois Bertucci Gene expression profiling of primary breast carcinomas using arrays of candidate genes
WO2002092854A2 (en) 2001-05-16 2002-11-21 Novartis Ag Genes expressed in breast cancer as prognostic and therapeutic targets
US20030073623A1 (en) 2001-07-30 2003-04-17 Drmanac Radoje T. Novel nucleic acid sequences obtained from various cDNA libraries
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US20070026417A1 (en) 2005-07-29 2007-02-01 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20090118175A1 (en) * 2005-05-06 2009-05-07 Macina Roberto A Compositions and Methods for Detection, Prognosis and Treatment of Breast Cancer
US20090275486A1 (en) 2006-05-16 2009-11-05 Nurith Kurn Nucleic acid separation and purification method based on reversible charge interactions
EP2589668A1 (en) 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
WO2009051734A1 (en) 2007-10-17 2009-04-23 The General Hospital Corporation Microchip-based devices for capturing circulating tumor cells and methods of their use
US9068181B2 (en) 2008-05-23 2015-06-30 The General Hospital Corporation Microfluidic droplet encapsulation
US20120252015A1 (en) 2011-02-18 2012-10-04 Bio-Rad Laboratories Methods and compositions for detecting genetic material
WO2010037134A2 (en) 2008-09-29 2010-04-01 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
US9625454B2 (en) 2009-09-04 2017-04-18 The Research Foundation For The State University Of New York Rapid and continuous analyte processing in droplet microfluidic devices
US20110166030A1 (en) 2009-09-30 2011-07-07 Yixin Wang Prediction of response to docetaxel therapy based on the presence of TMPRSSG2:ERG fusion in circulating tumor cells
EP4484577A3 (en) 2010-02-12 2025-03-26 Bio-Rad Laboratories, Inc. Digital analyte analysis
US20120329061A1 (en) 2010-03-11 2012-12-27 Board Of Regents, The University Of Texas System Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of cancer patients
EP2845911B1 (en) * 2010-03-31 2016-05-18 Sividon Diagnostics GmbH Method for breast cancer recurrence prediction under endocrine treatment
AU2015268617A1 (en) * 2010-03-31 2016-01-07 Sividon Diagnostics Gmbh Method for breast cancer recurrence prediction under endocrine treatment
US9650629B2 (en) 2010-07-07 2017-05-16 Roche Molecular Systems, Inc. Clonal pre-amplification in emulsion
CA2808417A1 (en) 2010-08-18 2012-02-23 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
EP2678448A4 (en) 2011-02-22 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L CIRCULATING BIOMARKERS
WO2012135397A2 (en) * 2011-03-29 2012-10-04 Lisanti Michael P Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
JP6247218B2 (ja) 2011-10-24 2017-12-13 ザ ジェネラル ホスピタル コーポレイション 癌のバイオマーカー
WO2014008155A1 (en) 2012-07-02 2014-01-09 The General Hospital Corporation Diagnosis and monitoring treatment of prostate cancer
AU2013302867A1 (en) 2012-08-13 2015-02-26 The Regents Of The University Of California Methods and systems for detecting biological components
AU2013315128B2 (en) 2012-09-14 2019-01-03 Memorial Sloan-Kettering Cancer Center Genes associated with dasatinib sensitivity
WO2014047285A1 (en) 2012-09-19 2014-03-27 Paraskevi Giannakakou Identifying taxane sensitivity in prostate cancer patients
WO2014075067A1 (en) * 2012-11-12 2014-05-15 Nanostring Technologies, Inc. Methods to predict breast cancer outcome
US20140303005A1 (en) 2013-04-05 2014-10-09 Raindance Technologies, Inc. Rare cell analysis after negative selection
CN105636594A (zh) 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
EP3058316B1 (en) 2013-10-18 2019-03-13 The General Hospital Corporation Microfluidic sorting using high gradient magnetic fields
SG11201607339VA (en) * 2014-03-13 2016-10-28 Hoffmann La Roche Methods and compositions for modulating estrogen receptor mutants
WO2015177184A1 (en) * 2014-05-21 2015-11-26 F. Hoffmann-La Roche Ag Methods of treating pr-positive, luminal a breast cancer with pi3k inhibitor, pictilisib
CN107003300B (zh) * 2014-12-12 2020-02-07 凯尔科迪股份有限公司 测量erbb信号传导通路活性以诊断和治疗癌症患者的方法
WO2016131924A1 (en) 2015-02-20 2016-08-25 Comelz S.P.A. Method for cutting natural hides and the like
MA45480A (fr) 2015-03-12 2018-01-17 Janssen Pharmaceutica Nv Marqueurs d'arnm à base de sang total pour prédire un cancer de la prostate, et leurs procédés de détection
EP3274476B1 (en) 2015-03-25 2023-06-07 The General Hospital Corporation Digital analysis of circulating tumor cells in blood samples
EP3985127A1 (en) * 2016-10-27 2022-04-20 The General Hospital Corporation Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers

Similar Documents

Publication Publication Date Title
JP2020501517A5 (https=)
Sato et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Wang et al. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor
Mego et al. Expression of epithelial–mesenchymal transition‐inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy
Vriens et al. MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer
Fabris et al. The potential of microRNAs as prostate cancer biomarkers
Singh et al. Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells
Redis et al. CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations
Zhang et al. Up-regulation of LncRNA SNHG20 predicts poor prognosis in hepatocellular carcinoma
Song et al. Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients
Markou et al. Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long follow-up
MacConaill et al. Prospective enterprise-level molecular genotyping of a cohort of cancer patients
Chan et al. SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients
Takeshita et al. Prognostic role of PIK 3 CA mutations of cell‐free DNA in early‐stage triple negative breast cancer
Daniunaite et al. Clinical significance of miRNA host gene promoter methylation in prostate cancer
Lieb et al. Serum levels of miR-320 family members are associated with clinical parameters and diagnosis in prostate cancer patients
US20170107577A1 (en) Determining Cancer Aggressiveness, Prognosis and Responsiveness to Treatment
Kulda et al. Prognostic significance of TMPRSS2-ERG fusion gene in prostate cancer
Chang et al. Review of microRNA in osteosarcoma and chondrosarcoma
Peng et al. Long noncoding RNA LUNAR1 associates with cell proliferation and predicts a poor prognosis in diffuse large B-cell lymphoma
Chimonidou et al. Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer
Liu et al. Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer
Schubert et al. Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development?
Marino et al. Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression
Suer et al. MicroRNAs as prognostic markers in prostate cancer